Zhitong Finance App News, Yifang Biotech (688382.SH) announced that the registered phase III clinical study of nomelcitinib (D-2570), a novel oral selective inhibitor targeting Tyk2JH2 developed by the company to treat moderate to severe plaque psoriasis, reached a major end point and a key secondary end point. The results of this study mark a milestone in the clinical development of nomelcitinib (D-2570) in the field of psoriasis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.